FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

278221000202100: Bimekizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Sep 2023. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
5266542016 Bimekizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
5266543014 Bimekizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Bimekizumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Bimekizumab (substance) Is a Interleukin receptor antagonist true Inferred relationship Some
Bimekizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin receptor antagonist (disposition) true Inferred relationship Some
Bimekizumab (substance) Is a Immunosuppressant (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Bimekizumab 160 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Bimekizumab (substance) Inferred relationship Some 1
Bimekizumab 160 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Bimekizumab (substance) Inferred relationship Some 1
Product containing only bimekizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Bimekizumab (substance) Inferred relationship Some 1
Bimekizumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Bimekizumab (substance) Inferred relationship Some 1
Product containing bimekizumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Bimekizumab (substance) Inferred relationship Some 1
Product containing only bimekizumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Bimekizumab (substance) Inferred relationship Some 1

Reference Sets

GB English

US English

Back to Start